Him & Hers, WW down on Novo attempt to restrict compounded semaglutide

seekingalpha
24 Oct 2024

Sundry Photography/iStock Editorial via Getty Images

  • Hims & Hers Health (NYSE:HIMS) and WW International (NASDAQ:WW) are both down significantly in Wednesday trading following Novo Nordisk's (NVO) attempt to get the U.S. FDA to ban the manufacture of compounded semaglutide.
  • The Danish drugmaker has asked the agency

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10